USWM-AP2-3000: A Phase 3, Open-Label Study of the Safety, Efficacy, and Tolerability of Apopmorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients with Unsatisfactory Control on Available Therapy

August 17, 2018
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD
Parkinson's Disease, PD, Advanced Parkinson's Disease, Apomorphone, Parkinsons Disease
Accepting Participants